New York, June 11, 2026, 10:05 EDT
- Propanc Biopharma said it okayed up to $5 million for share buybacks. PPCB jumped in early Nasdaq action.
- The buyback stands out. The company reported just $443,702 in cash as of March 31.
- Investors want to see if Propanc gets PRP into its Phase 1b first-in-human cancer trial that’s planned for later this year.
Propanc Biopharma, Inc. shares jumped Thursday as the company set a $5 million stock buyback plan. Investors saw the buyback as a vote of confidence from management for the beaten-down Nasdaq name. PPCB was last seen at $6.04, up $4.69 from Wednesday’s $1.35 close, after hitting $6.64 earlier on strong volume.
PPCB’s story flipped after the announcement. On Wednesday, shares were stuck near the low end of the post-reverse-split range. By Thursday morning, traders had to factor in a buyback authorization that stands out for a company with only about 2.28 million post-split shares outstanding, based on May’s reverse-split disclosure.
Propanc said its board has cleared a plan to buy back up to $5 million of its common stock. The company may buy shares through open-market buys, private transactions, block trades, accelerated repurchases or preset Rule 10b5-1 plans. A share buyback can cut the number of shares trading and boost the stake of remaining holders, but only if the company follows through.
Chief Executive James Nathanielsz said the move is based on the company’s main asset, PRP. “We believe we are undervalued significantly,” Nathanielsz said. He pointed to the planned Phase 1b first-in-human trial in 30 to 40 advanced cancer patients and PRP’s U.S. FDA orphan drug status in pancreatic cancer, which the company says may lead to seven years of exclusivity if approved. Propanc Biopharma, Inc.
The math tells the story. Propanc’s May estimate put the share count at 2.28 million post-split shares. With the stock closing at $1.35 before Thursday, that put PPCB’s market cap at about $3.1 million. The $5 million raise was bigger than that value. But with the stock spiking, those numbers don’t match up in the same way.
Propanc said a $5 million buyback does not mean it will actually buy that amount of stock. The company can change, pause or stop the program whenever it wants, and there is no set amount of shares it must buy. That warning is important—buyback news can push up thinly traded stocks long before it’s clear if any real money will be spent.
The company’s finances put the issue in focus. Propanc showed $443,702 in cash at March 31, reported no revenue for the nine months ending then, and posted a net loss of $14.29 million. The company used $4.08 million in operations cash over the period. Its most recent 10-Q flagged “substantial doubt” about its ability to keep going as a “going concern,” meaning it may not have enough cash to run normally for the next year without more funding or some form of relief.
Propanc has turned to financing as it pushes ahead with its plans. In its May quarterly update, the company said it entered a private placement deal for up to $100 million. It took in $1 million from Series C convertible preferred stock and another $1 million in a separate Series C-related investment by March 31. Propanc reported $14.33 million in total assets, $3.51 million in liabilities, and had $443,702 in cash at quarter end.
Investors aren’t just paying attention to financial moves. Propanc management is using the PRP program as the main reason for the buyback push. Back in May, the company said it hired a European CDMO to make PRP under GMP rules, which are needed for clinical drug production, ahead of a planned Phase 1b study in advanced solid-tumor patients.
The trial is still the hurdle for Propanc. The company has said it wants to file a clinical trial application before year-end. In May, Propanc said it’s working with FyoniBio GmbH on a pharmacokinetics assay to track how the drug acts in the body. For a biotech with no revenue, getting that filing in could matter more than any short-term move in the share price, since it’s the way to get the lead drug out of prep and into human testing.
Thursday’s rally could have investors getting ahead of what Propanc can deliver. The business doesn’t report any product revenue. It has flagged a going-concern risk and says more financing could mean limits on operations or a hit for shareholders. Buybacks often send a message of confidence, but here, that money could cut into budgets for manufacturing, regulatory costs or prepping trials—areas where the company still needs cash.
PPCB is moving more on its microcap capital structure than on usual biotech earnings trading right now. Investors are looking for proof the company can actually pay for its buyback and still move PRP ahead toward the clinical trial application that Propanc says is coming later this year. Another confidence statement doesn’t cut it.
